- Home
- TKNO vs AVIR Comparison
TKNO vs AVIR Comparison
Compare TKNO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- AVIR
- Stock Information
- Founded
- TKNO 1996
- AVIR 2012
- Country
- TKNO United States
- AVIR United States
- Employees
- TKNO N/A
- AVIR N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TKNO Health Care
- AVIR Health Care
- Exchange
- TKNO Nasdaq
- AVIR Nasdaq
- Market Cap
- TKNO 244.7M
- AVIR 276.9M
- IPO Year
- TKNO 2021
- AVIR 2020
- Fundamental
- Price
- TKNO $5.91
- AVIR $3.22
- Analyst Decision
- TKNO Buy
- AVIR Hold
- Analyst Count
- TKNO 2
- AVIR 1
- Target Price
- TKNO $5.00
- AVIR $6.88
- AVG Volume (30 Days)
- TKNO 269.2K
- AVIR 175.5K
- Earning Date
- TKNO 11-07-2024
- AVIR 11-07-2024
- Dividend Yield
- TKNO N/A
- AVIR N/A
- EPS Growth
- TKNO N/A
- AVIR N/A
- EPS
- TKNO N/A
- AVIR N/A
- Revenue
- TKNO $36,347,000.00
- AVIR N/A
- Revenue This Year
- TKNO $3.56
- AVIR N/A
- Revenue Next Year
- TKNO $13.31
- AVIR N/A
- P/E Ratio
- TKNO N/A
- AVIR N/A
- Revenue Growth
- TKNO N/A
- AVIR N/A
- 52 Week Low
- TKNO $1.16
- AVIR $2.77
- 52 Week High
- TKNO $7.92
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- TKNO 44.25
- AVIR 39.98
- Support Level
- TKNO $6.15
- AVIR $3.32
- Resistance Level
- TKNO $7.92
- AVIR $3.48
- Average True Range (ATR)
- TKNO 0.69
- AVIR 0.14
- MACD
- TKNO -0.17
- AVIR -0.01
- Stochastic Oscillator
- TKNO 0.50
- AVIR 9.09
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).